智通财经网·2025-12-15 09:41Core Viewpoint - Shanghai Pharmaceuticals (02607) has received a drug registration certificate from the Philippines Food and Drug Administration for its Hydroxychloroquine Sulfate Tablets, allowing the company to sell the product in the Philippines, which is expected to positively impact its overseas market expansion [1] Group 1: Product Approval - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The product was developed by Concordia Pharmaceuticals Inc and was first launched in the United States in 1955 [1] - Shanghai Pharmaceuticals' Hydroxychloroquine Sulfate Tablets were approved for domestic sale in China in December 1999 and passed the consistency evaluation for generic drugs in December 2021 [1] Group 2: Financial Aspects - The company has not incurred additional R&D expenses for the product's launch in the Philippines, with only registration-related costs amounting to approximately RMB 50,000 [1] - According to IQVIA data, the total sales revenue for Hydroxychloroquine Sulfate Tablets (200 mg) in the Philippines is projected to be USD 4.13 million in 2024 [1] Group 3: Market Impact - The approval signifies the company's qualification to sell the product in the Philippine market, which is expected to have a positive impact on the company's overseas market expansion and accumulate valuable experience [1]